---
title: "Varegacestat (AL102) in Desmoid tumors: AL102-503"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: AL102-503. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 12 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/al102-503"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: AL102-503

<a id="heading-3.1.6"></a>

## 3.1.6 AL102-503

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Pharmacokinetics, safety, and tolerability in hepatic impairment

> “A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Varegacestat in Participants With or Without Hepatic Impairment”
> “This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Registry status, dates, and sites

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-503” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-03-07” |
| Primary completion (actual) | “2025-11-05” |
| Study completion (actual) | “2026-03-06” |
| First posted | “2025-02-24” |
| Last update posted | “2026-03-10” |
| Sites | “Orlando Clinical Research Center”; “The Texas Liver Institute” |

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Open-label, single-dose, parallel-group design with matched controls

> “This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.”
> “The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio.”
> “Healthy participants (Group 1) will be matched by age (± 10 years), body mass index (BMI, ± 15%), and sex to participants with mild to moderate hepatic impairment (Groups 2 and 3).”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.3-2"></a>

#### Conditional enrollment of participants with severe hepatic impairment

> “Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.3-3"></a>

#### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Hepatic impairment by Child-Pugh category

> “Considered to have HI (of any etiology) that has been clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to dosing per the PI and Sponsor and is likely to remain stable throughout the study.”
> “Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:”
> “Mild: ≥5 and ≤6 [Category A]; or”
> “Moderate: ≥7 and ≤9 [Category B]; or”
> “Severe: ≥10 and ≤15 [Category C].”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.4-2"></a>

#### Healthy matched participants aged 18 to 84 years

> “Healthy, adult, male or female (of nonchildbearing potential only), 18 to 84 years of age, inclusive, at the screening visit. Participant will be matched by age (± 10 years) and sex to a participant with hepatic impairment (HI).”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Single oral dose of varegacestat on day 1

> “Single oral dose of varegacestat administered on study day 1”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Primary endpoints: AUC and Cmax of varegacestat and metabolite

> “PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.”
> “AUC0-t varegacestat and metabolite”
> “AUC0-inf for varegacestat and metabolite”
> “Cmax for varegacestat and metabolite”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-3.1.6.6.1-2"></a>

##### Secondary endpoints: safety and tolerability

> “Number of subjects who experience treatment emergent adverse events (TEAEs)”
> “Number of subjects who experience abnormalities in vital signs and in clinical laboratory tests such as serum chemistry and hematology”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “35” |

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

No evidence found.

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

- AL102-503 is known only from its registry record. The record lists the study as “Completed”, with study completion on 2026-03-06, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so varegacestat exposure in hepatic impairment is unknown from public sources.
- The registry gives the actual enrollment as 35 participants but not their distribution across the healthy, mild, moderate, and severe hepatic impairment groups. Enrollment of the severe group (Child-Pugh C) was planned only “if appropriate”, contingent on data from the first three groups.
- The design is open label with a single oral dose, and the registry record does not state the dose.

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
